Jaime Fensterl

发表

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

J. Barnard, G. Garcia-Manero, D. Steensma, 2016 .

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

A. Stamatoullas, K. Götze, P. Cony-Makhoul, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia.

F. Ali-Osman, W. Tse, J. Maciejewski, 2020, Clinical lymphoma, myeloma & leukemia.

Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

J. Barnard, G. Garcia-Manero, J. Maciejewski, 2016 .